Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899–910 (2006).•• A landmark study reporting efficacy results of natalizumab.
  Medline CASGoogle Scholar
• 2 Plavina T, Subramanyam M, Bloomgren G et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76(6), 802–812 (2014).•• A study describing patients with a higher risk for progressive multifocal leukoencephalopathy when treated with natalizumab.
  Medline CASGoogle Scholar
• 3 Bomprezzi R, Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther. Adv. Neurol. Disord. 7(5), 227–231 (2014).
  Medline CASGoogle Scholar
• 4 Cree B, De Sèze J, Fox R et al. Natalizumab effects during a 6-month dose interruption: relationship of pharmacokinetic (PK), pharmacodynamic (PD), and MRI measurements. Presented at: 65th Annual Meeting of the American Academy of Neurology. San Diego, CA, USA, 16–22 March 2013.
  Google Scholar
• 5 O'Connor PW, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76(22), 1858–1865 (2011).
  MedlineGoogle Scholar
• 6 Cree B, De Sèze J, Fox R et al. RESTORE Study: effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity. Presented at: 64th Annual Meeting of the American Academy of Neurology. New Orleans, LA, USA, 21–28 April 2012.
  Google Scholar
• 7 Fox R, Cree B, De Sèze J et al. RESTORE study: effects of natalizumab interruption on multiple sclerosis disease activity. Presented at: 4th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and 17th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). San Diego, CA, USA, 30 May 2012.• A study showing an increased relapse rate and higher MRI activity with natalizumab withdrawal.
  Google Scholar
• 8 Cordioli C, Rasia S, de Rossi N et al. Safety and efficacy of natalizumab infusions every eight weeks after a 24 month period of monthly infusions in multiple sclerosis patients. Presented at: 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands, 19–22 October 2011.
  Google Scholar
• 9 Herbert J, Ryerson L, Kister I et al. Establishment of a global registry for multiple sclerosis patients on extended dose natalizumab dosing. Presented at: 2014 Joint ACTRIMS-ECTRIMS Meeting. Boston, MA, USA, September 2014.
  Google Scholar
• 10 Herbert J, Ryerson LZ, Tornatore C et al. Multicenter retrospective study of extended dosing of natalizumab in multiple sclerosis: a strategy for mitigating risk of progressive multifocal leukoencephalopathy while maintaining efficacy? Presented at: 66th Annual Meeting of the American Academy of Neurology. Philadelphia, PA, USA, 26 April–3 May 2014.
  Google Scholar
• 11 Ryerson LZ, Herbert J, Foley J et al. Safety and efficacy of extended dose natalizumab in multiple sclerosis: an ongoing multicenter study. Presented at: 67th Annual Meeting of the American Academy of Neurology. Washington DC, USA, 18–25 April 2015.• A large multicenter study of extended dosing.
  Google Scholar
• 12 Foley J, Metzger R, Hoyt T et al. The effect of extended interval dosing and patient weight on long term natalizumab pharmacokinetics. Presented at: 67th Annual Meeting of the American Academy of Neurology. Washington DC, USA, 18–25 April 2015.
  Google Scholar
• 13 Chapagain ML, Verma S, Mercier F et al. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology 364(1), 55–63 (2007).
  Medline CASGoogle Scholar
• 14 Beppu M, Kawamoto M, Nukuzuma S et al. Mefloquine improved progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus. Intern. Med. 51(10), 1245–1247 (2012).
  Medline CASGoogle Scholar
• 15 Kurmann R, Weisstanner C, Kardas P et al. Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. J. Neurovirol. doi:10.1007/s13365-015-0340-4 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 16 Park JH, Ryoo S, Noh HJ et al. Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case Rep. Neurol. 3(3), 258–262 (2011).
  MedlineGoogle Scholar
• 17 Naess H, Glad S, Storstein A et al. Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurol. 18(10), 32 (2010).
  Google Scholar